NEW Late-Breaking Abstract Announced
The Society for Immunotherapy of Cancer (SITC) is excited to announce one additional late-breaking abstract that will be presented during SITC 2016 next week. The trial in question, a prospective, randomized trial of pembrolizumab in advanced bladder cancer, was recently halted early due to the clear difference in outcomes between study arms.
Abstract Title: KEYNOTE-045: open-label, phase 3 study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
Session Date: Saturday, November 12
Session Time: 11:15 a.m. – noon
Presentation time: 11:45 a.m. – noon
Browse all abstract titles on the SITC 2016 meeting app in addition to session descriptions, faculty, exhibitors, and more. Access the 31st Annual Meeting & Associated Programs by downloading the SITC 2016 meeting app through the App Store (iOS) or Google Play (Android).
As a reminder, the abstract embargo will lift on Tuesday, November 8, at 8:00 a.m. EST, and all accepted regular abstracts will be accessible via a special supplement published in SITC’s official journal, the Journal for ImmunoTherapy of Cancer (JITC). All accepted late-breaking abstracts will be published on December 8 in JITC.
Advance Registration Closing Soon
 |
To accommodate additional interest in the newly added late-breaking abstract, SITC2016 advance registration will remain open through November 7, 2016. While onsite registration will be available, it is recommended that you take advantage of the advance registration option to ensure your place at the world's leading cancer immunotherapy conference and register now! As with all of our live programs, SITC members enjoy reduced registration rates. If you are not yet a SITC member, or have yet to renew your dues, simply apply or renew online to qualify for reduced SITC 2016 registration rates.
